59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (23rd October 2018) - Finn, R S; Kudo, M; Cheng, A-L; Wyrwicz, L; Ngan, R; Blanc, J F; Baron, A D; Vogel, A; Ikeda, M; Piscaglia, F; Han, K-H; Qin, S; et al.